Myovant Sciences Ltd MYOV:NYSE

RT Quote | Last NYSE, VOL From CTA | USD
Last | 2:21 PM EDT
22.72quote price arrow down-0.98 (-4.14%)
Volume
237,035
52 week range
13.42 - 30.90
Loading...
  • Open23.50
  • Day High23.51
  • Day Low22.64
  • Prev Close23.70
  • 52 Week High30.90
  • 52 Week High Date12/28/20
  • 52 Week Low13.42
  • 52 Week Low Date10/02/20

Key Stats

  • Market Cap2.092B
  • Shares Out92.08M
  • 10 Day Average Volume0.80M
  • Dividend-
  • Dividend Yield-
  • Beta2.85
  • YTD % Change-17.45

KEY STATS

  • Open23.50
  • Day High23.51
  • Day Low22.64
  • Prev Close23.70
  • 52 Week High30.90
  • 52 Week High Date12/28/20
  • 52 Week Low13.42
  • 52 Week Low Date10/02/20
  • Market Cap2.092B
  • Shares Out92.08M
  • 10 Day Average Volume0.80M
  • Dividend-
  • Dividend Yield-
  • Beta2.85
  • YTD % Change-17.45

RATIOS/PROFITABILITY

  • EPS (TTM)-3.13
  • P/E (TTM)-7.25
  • Fwd P/E (NTM)-11.73
  • EBITDA (MRQ)-281.773M
  • ROE (MRQ)-622.01%
  • Revenue (MRQ)67.05M
  • Gross Margin (MRQ)85.63%
  • Net Margin (MRQ)-423.49%
  • Debt To Equity (MRQ)-89.76%

EVENTS

  • Earnings Date11/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Myovant Sciences Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the...
Myrtle Potter
Chairman
David Marek
Chief Executive Officer
Uneek Mehra
Chief Financial Officer
Matthew Lang
General Counsel
Address
Ste 1 3rd Fl, 11/12 St. James's Square
London
SW1Y 4LB
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
SRNE
Sorrento Therapeutics Inc
7.69-0.45-5.53%
RVNC
Revance Therapeutics Inc
29.16-0.50-1.67%
CYTK
Cytokinetics Inc
34.40-0.51-1.46%
RVMD
Revolution Medicines Inc
28.83-0.95-3.19%
DCPH
Deciphera Pharmaceuticals Inc
33.56-0.37-1.09%